Treatment Algorithm for Relapsed/Refractory DLBCL

Tips from experts on how to think about and manage adverse events in patients with diffuse large B-cell lymphoma.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Davide Rossi, MD, spoke about the impact of the MZL workshop and his hopes for the future of treatment and medicine in MZL.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.

As MZL is such a rare subtype of lymphoma, it can be hard to find or begin trials geared specifically toward this population.